First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 46.35 CNY -2.11%
Updated: Apr 29, 2024

Tibet Rhodiola Pharmaceutical Holding Co
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tibet Rhodiola Pharmaceutical Holding Co
Net Income (Common) Peer Comparison

Comparables:
1099
S
601607
600998
C
600511
000963

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Net Income (Common)
¥800.9m
CAGR 3-Years
24%
CAGR 5-Years
30%
CAGR 10-Years
40%
Sinopharm Group Co Ltd
HKEX:1099
Net Income (Common)
¥8.9B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
15%
S
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Net Income (Common)
¥3.8B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
5%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Net Income (Common)
¥2.2B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
17%
C
China National Medicines Corp Ltd
SSE:600511
Net Income (Common)
¥2.1B
CAGR 3-Years
16%
CAGR 5-Years
9%
CAGR 10-Years
18%
Huadong Medicine Co Ltd
SZSE:000963
Net Income (Common)
¥2.7B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
17%

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common)?
Net Income (Common)
800.9m CNY

Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common) amounts to 800.9m CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
40%

Over the last year, the Net Income (Common) growth was 117%. The average annual Net Income (Common) growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 24% over the past three years , 30% over the past five years , and 40% over the past ten years .